MD Newsline Oncology Brief

MD Newsline
  • 0.0 (0)
  • Medicine
  • Weekly

Welcome to MD Newsline Oncology Brief, your go-to source for concise, expert-led updates in the ever-evolving field of oncology. Designed for busy healthcare professionals, this podcast delivers focused insights from leading oncologists, researchers, and clinical experts. Each episode highlights the latest breakthroughs in cancer care, including emerging therapies, clinical trial updates, and practical treatment strategies. From immunotherapy advancements to real-world patient care approaches, we break down complex topics into clear, actionable takeaways. Whether you're an oncologist, physician, or part of the broader medical community, Oncology Brief helps you stay current without the noise. Our mission is to provide relevant, timely knowledge that supports better decision-making and improved patient outcomes. Tune in for quick, impactful conversations shaping the future of cancer care.

  1. 4d ago

    AI, HER2-Low, and the Future of Precision Oncology

    In this episode of MD Newsline, Dr Frederick Howard, breast oncologist at the University of Chicago and leader of a research group focused on AI-driven biomarker development, explores the rapidly evolving role of artificial intelligence in breast cancer care. Dr. Howard provides a comprehensive overview of how AI is being integrated into oncology—from radiographic imaging and digital pathology to clinical decision support and language models. He discusses both the promise and the practical challenges of deploying AI tools in real-world workflows, including validation standards, regulatory guardrails, and ethical considerations. The conversation also dives into emerging applications such as AI-based HER2 quantification, recurrence risk prediction from H&E slides, and the potential for multimodal models to transform precision medicine. Episode Highlights: AI in Radiology and Mammography Dr. Howard explains the evolution from early computer-aided detection systems to modern deep learning algorithms trained on millions of mammograms. He discusses emerging AI-driven breast cancer risk prediction tools derived directly from imaging and how they may enhance early detection strategies. Digital Pathology and Biomarker Development AI tools are increasingly capable of quantifying immunohistochemistry and identifying features beyond human visual interpretation. Dr. Howard highlights research presented at major oncology meetings demonstrating improved concordance in HER2-low classification and improved reproducibility in biomarker scoring. Predicting Recurrence Risk Without Genomic Testing One of the most promising areas involves AI models trained on H&E slides to predict recurrence risk—potentially matching or exceeding established genomic assays such as Oncotype DX and MammaPrint. Dr. Howard discusses the validation challenges required before these tools can replace or complement genomic testing in clinical practice. HER2-Low Classification and Antibody-Drug Conjugates The discussion explores limitations of traditional HER2 immunohistochemistry, especially at the lower end of expression. AI-based quantitative approaches may improve patient stratification for HER2-directed antibody-drug conjugates, though questions remain about predictive thresholds and biological mechanisms. Language Models in Oncology Practice Dr. Howard examines the growing use of large language models for literature review, documentation support, and clinical trial matching. He emphasizes the need for HIPAA-compliant systems, clinician oversight, and standardized evaluation frameworks to ensure safe and responsible deployment. Ethics, Governance, and Over-Reliance From data privacy to clinical accountability, the episode addresses the ethical considerations surrounding AI in cancer care. Dr. Howard cautions against over-reliance on AI systems and underscores the importance of maintaining clinician expertise and critical thinking. The Future: Multimodal AI and Precision Medicine Looking ahead, Dr. Howard envisions a future where digital pathology, genomics, imaging, and clinical data converge into multimodal AI systems capable of delivering truly personalized treatment recommendations. He stresses that large-scale data sharing and collaboration will be essential to realizing this potential. Key Takeaway Artificial intelligence is no longer theoretical in oncology—it is actively shaping diagnostics, risk stratification, and treatment selection in breast cancer. However, rigorous validation, ethical governance, and thoughtful integration into clinical workflows are critical to ensuring that AI enhances—rather than replaces—expert clinical judgment. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Frederick Howard: Here

    AI, HER2-Low, and the Future of Precision Oncology

  2. Oct 20

    Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South

    In this episode of MD Newsline, Dr. Janeane N. Anderson, Assistant Professor at the University of Tennessee Health Science Center and breast cancer researcher, shares insights from the ACCESS Study—an innovative qualitative research initiative focused on understanding why Black women in the Mid-South region are disproportionately diagnosed with advanced-stage breast cancer. Dr. Anderson discusses structural barriers, community-based recruitment strategies, and the importance of centering lived experiences in oncology research. She also highlights the critical need for equitable research participation, race- and gender-concordant research teams, and stronger clinician engagement to improve outcomes for underserved populations. Episode Highlights: Understanding Advanced-Stage Breast Cancer in the Mid-South Dr. Anderson explains how the Mississippi Delta region represents a "cancer hotspot," with higher rates of late-stage diagnoses and mortality among Black women. She explores how structural vulnerability, transportation challenges, cultural norms, and fragmented healthcare systems contribute to disparities. The ACCESS Study: A Community-Centered Research Design The ACCESS Study is a three-year qualitative investigation examining socio-ecological factors that increase the likelihood of de novo metastatic breast cancer diagnoses among Black women. Dr. Anderson outlines her multi-method approach, including: ·        In-depth interviews with photo elicitation ·        Ethnographic "go-alongs" in participants' neighborhoods ·        Observations during clinic visits ·        Interviews with regional clinicians This immersive methodology allows researchers to understand not just clinical outcomes, but the lived realities shaping patient journeys. Barriers to Recruitment and Participation Recruiting women with metastatic breast cancer presents unique challenges. Dr. Anderson discusses barriers such as: ·        Health status and treatment burden ·        Caregiving responsibilities ·        Transportation and rural geography ·        Income instability and housing challenges ·        Research mistrust rooted in sociohistorical and contemporary inequities She emphasizes that participation barriers are often structural—not a lack of interest. Recruitment Strategies That Worked Dr. Anderson highlights the importance of race- and gender-concordant research teams, which foster trust and cultural understanding. Additional effective strategies included: ·        Leveraging electronic health records for efficient identification ·        Community-based outreach in churches, libraries, salons, and local organizations ·        Multiple consent touchpoints to address concerns and build rapport Her key message to clinicians: Ask. Many eligible patients are interested in research—but are never invited. Moving Beyond Accrual Metrics Dr. Anderson argues that equitable research should not be measured by numbers alone. Individual stories—"n of 1" experiences—reveal intersectional traumas and systemic barriers that large datasets may overlook. She advocates for qualitative methodologies to better understand the "why" behind disparities. Sexual Health and Survivorship At the San Antonio Breast Cancer Symposium, Dr. Anderson also noted the need for greater focus on oncosexology. Sexual health remains one of the most unmet needs in breast cancer survivorship, impacting quality of life, adherence, and overall well-being. Key Takeaway Dr. Anderson underscores that addressing disparities in advanced breast cancer requires more than clinical innovation. It demands community engagement, culturally concordant research teams, clinician advocacy, and methodologies that center the lived experiences of Black women. True equity begins with listening—and asking. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Janeane N. Anderson: Here

    Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South

  3. Oct 13

    Understanding Cancer Disparities, Mistrust, and Access to Care

    In this episode of MD Newsline, Dr. Jordonna Brown, a medical oncologist at Kings County Hospital in New York City, shares her frontline experience caring for patients in a safety-net hospital setting. Speaking from the San Antonio Breast Cancer Symposium (SABCS), Dr. Brown discusses cancer disparities, late-stage presentation, mistrust in the healthcare system, and the evolving landscape of breast cancer treatment. She offers a candid look at the social determinants of health shaping patient outcomes—from delayed screening and misconceptions about chemotherapy to barriers in long-term adherence and clinical trial participation. Episode Highlights: Late-Stage Presentation and Screening Gaps Dr. Brown highlights a concerning trend: many patients present with advanced-stage breast cancer due to missed routine mammograms. Barriers include misconceptions about radiation exposure, fear of pain, religious beliefs, and lack of awareness about updated screening guidelines starting at age 40. Mistrust and Chemotherapy Misconceptions One of the most persistent challenges is distrust in the medical system. Patients often fear that chemotherapy may be more harmful than beneficial. Dr. Brown emphasizes the importance of patient-centered communication, empathy, and transparent education to build trust and empower informed decisions. Younger Patients and Aggressive Disease Breast and colon cancers are increasingly diagnosed in younger populations. In women under 40, breast cancer often demonstrates more aggressive tumor biology. Younger patients also face unique psychosocial challenges, including body image concerns, fertility considerations, career disruptions, and adherence to long-term maintenance therapy. Socioeconomic Barriers and Access to Care Financial instability, employment loss, transportation issues, and food insecurity can significantly impact adherence and long-term outcomes. Dr. Brown discusses how institutional support—such as social services, transportation programs, counseling, and food banks—helps mitigate these barriers. Clinical Trials and Underrepresentation Dr. Brown notes persistent skepticism around clinical trials among underrepresented communities. She underscores the need for improved education, emphasizing that today's standard treatments are the result of prior clinical trials—and that participation advances care for future generations. Emerging Therapies and Personalized Medicine At SABCS, Dr. Brown was encouraged by advances in early-stage hormone-positive breast cancer, including new selective estrogen receptor degraders (SERDs) such as giredestrant, which may offer improved tolerability compared to traditional endocrine therapies. She also discusses the growing role of artificial intelligence in shaping cancer care and the importance of ensuring diverse data representation in AI-driven tools. Mental Health and Survivorship The emotional and social impact of a cancer diagnosis often extends beyond treatment. Family dynamics, job security, and mental health are frequently under-addressed areas. Dr. Brown advocates for integrated palliative care, psychotherapy services, and survivorship groups to support patients holistically. Key Takeaway Addressing breast cancer disparities requires more than medical innovation—it demands trust-building, education, equitable access, and culturally sensitive communication. By partnering with patients, improving representation in clinical research, and strengthening community-based support systems, clinicians can meaningfully improve outcomes across diverse populations.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Jordonna  Brown: Here

    Understanding Cancer Disparities, Mistrust, and Access to Care

  4. Oct 6

    Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis

    In this episode of MD Newsline, Dr. Theodoros Karantanos, Assistant Professor of Medical Oncology at the Johns Hopkins University Sidney Kimmel Cancer Center, discusses the emerging role of inflammatory signaling in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Karantanos shares insights from his laboratory research exploring how inflammatory pathways—particularly interferon gamma and JAK-STAT signaling—contribute to treatment resistance, including resistance to venetoclax. He also highlights the impact of TP53 mutations, bone marrow microenvironment dynamics, and post-translational modifications in shaping disease progression and therapeutic response. Episode Highlights: Inflammatory Signaling and Venetoclax Resistance High-risk MDS and AML frequently demonstrate upregulation of inflammatory pathways. Dr. Karantanos explains how interferon gamma signaling activates the JAK-STAT cascade (JAK1/2, STAT1/3/5), leading to transcriptional programs associated with resistance to venetoclax and chemotherapy. The Role of TP53 in Driving Inflammation Loss of TP53 function not only impairs apoptosis but may intrinsically upregulate interferon gamma signaling within leukemic cells. This cell-intrinsic inflammatory activation may partially explain why TP53-mutated MDS and AML remain particularly difficult to treat. Post-Translational Modifications as Resistance Drivers Phosphorylation and ubiquitination play central roles in regulating inflammatory cascades. Dr. Karantanos emphasizes that proteomic and phospho-signature analyses are essential, as RNA expression alone cannot fully capture pathway activation under therapeutic pressure. Bone Marrow Microenvironment and Cytokine Crosstalk The bone marrow niche—including fibroblasts, adipocytes, endothelial cells, and immune subsets—contributes to resistance through cytokine secretion (e.g., IL-1β, TNF-α) and drug metabolism. These interactions reshape therapeutic exposure and promote survival of malignant clones. Monocytic Leukemias and Inflammatory Activation Monocytic AML subtypes (M4/M5) appear particularly enriched in inflammatory signaling, including interferon gamma and TNF-α activation. These subsets may represent high-priority targets for inflammation-modulating strategies. Targeting Inflammatory Pathways: Translational Strategies Potential therapeutic approaches include IRAK1/IRAK4 inhibitors, JAK pathway modulation, and antibody-drug conjugates targeting downstream interferon-regulated surface proteins such as CCRL2 and ICAM-1. Combination and triplet regimens may offer future improvements over venetoclax-based standards. Single-Cell and Spatial Transcriptomics Dr. Karantanos highlights the importance of computational biology, single-cell RNA sequencing, and spatial transcriptomics in deciphering the complex inflammatory networks within the bone marrow microenvironment. These technologies are critical for identifying actionable nodes and refining patient stratification. Key Takeaway Inflammatory signaling is not merely a bystander in myeloid neoplasms—it is a central driver of disease evolution and therapeutic resistance. Integrating inflammatory biomarkers, post-translational pathway profiling, and microenvironmental analysis may unlock new precision strategies for high-risk MDS and AML, particularly in TP53-mutated and monocytic subtypes where unmet need remains greatest. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact With Dr. Theodoros Karantanos: Here

    Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis

  5. Sep 29

    Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes

    In this episode of MD Newsline, Dr. Marco Ruella, Associate Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, joins us from the American Society of Hematology (ASH) meeting to discuss a paradigm-shifting topic: host factors in cancer immunotherapy. Dr. Ruella explores how biological sex, aging, chronic inflammation, obesity, exercise, and the microbiome influence responses to therapies such as checkpoint inhibitors and CAR T-cell therapy. The conversation highlights emerging data, translational research, and the growing need to capture holistic patient information to optimize outcomes. Episode Highlights: Why Host Factors Matter in Immunotherapy Traditional clinical trials focus heavily on tumor biology, but host characteristics—including sex, age, metabolic state, and lifestyle—also shape immune responsiveness. Dr. Ruella explains how incorporating these variables can help explain why only a subset of patients achieve durable benefit. Sex-Based Differences in Immune Response Research suggests meaningful biological differences in cancer incidence, immune activation, and treatment outcomes between males and females. Female patients often demonstrate a more "inflamed" or "hot" tumor microenvironment, potentially contributing to stronger immune responses. Hormonal influences, X-linked immune genes, and lifestyle factors may all contribute. Chronic vs. Acute Inflammation Inflammation is a double-edged sword. While acute inflammation after therapy can enhance anti-tumor effects, chronic baseline inflammation is associated with poorer outcomes and greater toxicity in CAR T-cell therapy. Biomarkers such as ferritin, IL-6, CRP, and ESR may help stratify risk. Aging and Biological Fitness Chronological age alone does not predict immunotherapy outcomes. Instead, biological fitness and muscle mass (sarcopenia) may be more relevant predictors of response and toxicity. Emerging research aims to better define "biological age" to guide treatment decisions. Microbiome, Diet, and Metabolism Dr. Ruella shares compelling data linking gut microbiome diversity to CAR T-cell efficacy. Antibiotic exposure before therapy has been associated with poorer outcomes. Additionally, ketogenic diets and ketone bodies such as beta-hydroxybutyrate are being explored to enhance T-cell function in clinical trials. Exercise as an Immune Modulator Short-term exercise can mobilize NK cells and T cells into circulation, potentially priming the immune system before immunotherapy. Ongoing trials are investigating whether structured exercise programs may improve treatment efficacy. AI, Wearables, and the Future of Data Capture To fully understand host factors, clinicians must systematically collect data on diet, exercise, sleep, and inflammation. Wearables, mobile applications, and artificial intelligence may enable more comprehensive, multi-omic profiling and personalized immunotherapy strategies. Key Takeaway Cancer immunotherapy is not determined solely by tumor biology—it is profoundly shaped by the host. Sex differences, chronic inflammation, metabolic health, and lifestyle factors all influence immune function and treatment response. Integrating these variables into clinical research and real-world practice may unlock more precise, equitable, and effective immunotherapy strategies.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr Marco Ruella: Here

    Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes

  6. Sep 22

    What's Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence

    In this episode of MD Newsline,  Dr. Dejah Blake, a fifth-year PhD candidate at Emory University, joins us from the American Society of Hematology (ASH) conference to discuss the rapidly evolving landscape of CAR T-cell therapy. Dejah shares insights into engineering next-generation CAR T cells, improving accessibility through in vivo manufacturing, and addressing diversity gaps in clinical research. From armored CARs to gene editing and humanized mouse models, this conversation explores how innovation and equity must move forward together in advancing cancer immunotherapy. Episode Highlights: In Vivo CAR T Cells and Accessibility Traditional CAR T-cell therapy is often described as a "boutique" treatment—highly personalized and complex to manufacture. Dejah explains how in vivo CAR T strategies, including viral vectors and gene-editing approaches, could offer more accessible, potentially off-the-shelf options. Reducing manufacturing time and cost may significantly expand patient access. Gene Editing and the Next Frontier Gene editing technologies are reshaping how scientists design immune cells. Dejah discusses how advances in vector engineering, nanoparticles, and genome modification are transforming the field—not just for cancer, but for broader therapeutic applications. Armored CAR T Cells and Micro-Pharmacies Armored CAR T cells—engineered to secrete cytokines or other immune-modulating factors—represent an exciting innovation. These enhanced cells may help overcome tumor heterogeneity, antigen escape, and hostile tumor microenvironments, particularly in solid tumors. Persistence and the Tumor Microenvironment One of the biggest challenges in CAR T-cell therapy is ensuring persistence in immunosuppressive tumor environments. The discussion explores strategies to generate stem cell–like CAR T cells, balance memory and effector functions, and resist chronic antigen stimulation. Preclinical Models and Translational Science Dejah explains the importance—and limitations—of mouse models, including humanized and patient-derived xenograft (PDX) systems. While essential for mechanistic insight, these models do not always predict first-in-human outcomes, underscoring the need for thoughtful translational design. Retrospective Data, AI, and Clinical Blind Spots As more patients receive CAR T therapy, retrospective analyses are revealing patterns in durability, toxicity, and response. The conversation also addresses data blind spots—particularly regarding racial, socioeconomic, and age diversity—and emphasizes the importance of equitable representation in clinical research. Bridging Bench to Bedside Dejah highlights the growing collaboration between academia and industry in advancing cell therapy. Funding models, clinician-researcher partnerships, and patient-centered translational thinking are essential to moving discoveries from laboratory to clinic responsibly. Key Takeaway The future of CAR T-cell therapy depends not only on technological innovation—such as gene editing and in vivo engineering—but also on accessibility, diversity, and translational collaboration. By combining scientific rigor with equity-focused research, the next generation of immunotherapy can become more effective, scalable, and inclusive.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Dejah Blake: Here

    What's Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence

  7. Sep 15

    From Awareness to Action: Cancer Prevention & Patient Empowerment

    In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure, and the role of multidisciplinary care teams in supporting patients throughout their cancer journey. Episode Highlights Shifts in Breast and Prostate Cancer Detection Dr. Anupindi discusses increased awareness and earlier diagnosis of prostate cancer, particularly among younger men, driven by public education and PSA testing. She also reflects on breast cancer screening programs and the ongoing challenge of improving participation in minority and underserved communities. Cancer Awareness and Cultural Barriers Drawing from her experience working with South Asian communities, Dr. Anupindi addresses misconceptions around cancer, cultural taboos, and the importance of education in encouraging early screening and timely diagnosis. Younger Patients and Aggressive Disease Biology Younger breast cancer patients often present with more aggressive disease. Dr. Anupindi explains why oncologists tend to take a more proactive treatment approach in this population and highlights the role of hereditary cancer risk and hormonal factors. Key Advances from ESMO and Recent Trials Dr. Anupindi shares highlights from major oncology meetings, including discussions around reducing chemotherapy exposure in HER2-positive and hormone receptor–positive breast cancer. She also explains the clinical significance of trials focused on hormone resistance and targeted combination therapies. Fertility, Pregnancy, and Cancer Treatment The conversation explores data supporting temporary interruption of endocrine therapy for young women wishing to conceive. Dr. Anupindi emphasizes that cancer survivorship should include quality-of-life considerations, including fertility preservation and family planning. Access, Affordability, and Global Equity in Cancer Care Dr. Anupindi compares treatment access across healthcare systems, discussing regulatory pathways, cost considerations, and research into lower-dose therapies that may expand access without compromising outcomes. Technology, AI, and Precision Oncology From artificial intelligence in imaging and pathology to biomarker-driven therapies, Dr. Anupindi reflects on how technology is shaping more precise, efficient, and personalized cancer care. Multidisciplinary Care and Patient Support Team-based care is central to effective oncology treatment. Dr. Anupindi highlights the essential roles of nurses, radiographers, palliative care teams, and support workers in addressing patients' medical, psychological, and social needs. Quality of Life and Patient-Reported Outcomes As cancer treatments extend survival, Dr. Anupindi stresses the growing importance of quality-of-life measures in clinical trials and treatment decision-making, ensuring patients live better, not just longer. Key Takeaway Dr. Anupindi underscores that modern oncology is no longer focused solely on survival outcomes. Early detection, culturally sensitive education, targeted therapies, and quality-of-life considerations are essential to delivering truly patient-centered cancer care. Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Aruna Anupindi:  Here

    From Awareness to Action: Cancer Prevention & Patient Empowerment

  8. Sep 8

    AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps

    In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also addressing ethical considerations, data fairness, and the future of AI-driven decision-making in medicine. Episode Highlights AI in Clinical Trial Design and Drug Development Dr. Prelaj explains how AI tools are dramatically improving success rates in early-phase clinical trials. Technologies such as AlphaFold and predictive modeling are helping researchers identify promising drug targets, reduce trial failures, and optimize trial design before patients are enrolled. Predicting Trial Success and Reducing Failure AI-powered platforms can analyze historical clinical trial data to forecast the likelihood of success in Phase I, II, and III studies. Dr. Prelaj discusses how these insights benefit pharmaceutical companies, investigators, and ultimately patients by reducing exposure to ineffective treatments. Virtual Trials and Real-World Data Integration The conversation explores how virtual and pragmatic trial models leverage real-world data to simulate outcomes, relax restrictive inclusion criteria, and make trials more accessible to diverse patient populations—without compromising scientific rigor. Clinical Trial Matching and Physician Efficiency Dr. Prelaj highlights AI-driven clinical trial matching tools that can reduce physician workload by nearly 50%, helping clinicians quickly identify the most appropriate trials for individual patients while prioritizing those with the greatest potential benefit. Patient Advocacy and AI-Powered Access to Trials AI is empowering patients to actively participate in their care. Dr. Prelaj discusses patient-facing tools that allow individuals to identify relevant trials, initiate informed conversations with physicians, and advocate for access to cutting-edge treatments. Data Democratization, Bias, and Fairness The episode addresses critical challenges surrounding data governance, paywalled research, and underrepresentation in clinical trials. Dr. Prelaj explains how synthetic data and fairness auditing can help reduce disparities across race, ethnicity, and rare disease populations. The Future of AI in Oncology: Agents and Digital Twins Looking ahead, Dr. Prelaj shares her excitement about AI agents and digital twin models—dynamic systems that mirror real patients over time to support clinical decision-making, personalize treatment strategies, and enhance precision oncology. Key Takeaway: Dr. Prelaj emphasizes that artificial intelligence is not replacing clinicians—but augmenting their expertise. By combining AI-driven insights with human judgment, oncology is entering a new era of smarter trials, more equitable care, and data-informed decision-making that has the potential to improve outcomes for patients worldwide.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Arsela Prelaj:  Here

    AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps
See All (26)

About

Welcome to MD Newsline Oncology Brief, your go-to source for concise, expert-led updates in the ever-evolving field of oncology. Designed for busy healthcare professionals, this podcast delivers focused insights from leading oncologists, researchers, and clinical experts. Each episode highlights the latest breakthroughs in cancer care, including emerging therapies, clinical trial updates, and practical treatment strategies. From immunotherapy advancements to real-world patient care approaches, we break down complex topics into clear, actionable takeaways. Whether you're an oncologist, physician, or part of the broader medical community, Oncology Brief helps you stay current without the noise. Our mission is to provide relevant, timely knowledge that supports better decision-making and improved patient outcomes. Tune in for quick, impactful conversations shaping the future of cancer care.

Information